Navigation Links
NovaBay Pharmaceuticals' Scientific Advisor Receives American Chemical Society's Highest Award

M. Frederick Hawthorne, Ph.D. Honored for Distinguished Service in the Field of Chemistry

EMERYVILLE, Calif., March 23 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Alternext: NBY) today announced that world-renowned scientist M. Frederick Hawthorne, Ph.D., a member of the Company's Scientific Advisory Board will be the recipient of the 2009 Priestley Medal, the highest honor awarded by the American Chemical Society (ACS). Dr. Hawthorne, who is co-director of the International Institute for Nano and Molecular Medicine at the University of Missouri-Columbia, will be presented this award for distinguished service in the field of chemistry at the Spring ACS National Meeting to be held this week in Salt Lake City, Utah.

"Dr. Hawthorne is a world-renowned scientist who has brought his impeccable credentials and expertise to NovaBay," said Dr. Ron Najafi, chairman and chief executive officer of NovaBay. "We are extremely proud and honored to have such a distinguished leader of the chemical community on our Scientific Advisory Board. We congratulate him on receiving the prestigious 2009 Priestley Medal."

Dr. Hawthorne has contributed to the development of NovaBay's Aganocide(R) class of antimicrobial molecules specifically designed by NovaBay to mimic the body's natural defense against infection. These compounds may deliver the same or better level of antimicrobial activity as is currently reached by common antibiotics without contributing to the growing rise in bacterial resistance. The Aganocide compounds have shown in preclinical trials to date to be highly effective against bacteria, viruses and fungi. They have also been demonstrated to be effective against bacteria in biofilm, for which most antibiotics are rendered ineffective. These compounds have a potentially broad therapeutic index providing a high degree of potency, good tolerability, together with dosing versatility and flexibility.

Dr. Hawthorne began his 60-year career in chemistry working with the element, boron. He created a wide variety of novel polyboranes and carboranes and discovered uses for these compounds for applications in medical imaging, drug delivery, neutron-based treatments for cancers and rheumatoid arthritis, catalysis and molecular motors. He also created a specific type of nanoparticle that selectively targets cancer cells for boron neutron capture therapy. Dr. Hawthorne was elected to the National Academy of Sciences in 1973 at the age of 44. Professor Hawthorne is the recipient of many awards and honors over his distinguished career. He has authored or co-authored more than 500 research articles, 30 patents and 10 book chapters. He has mentored and directed the research of nearly 200 Ph.D. students and postdoctoral associates from 21 countries. Thirty-five (35) now hold academic positions. Many have risen to high positions in industry and one was a space shuttle astronaut.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a mid-stage biopharmaceutical company developing first-in-class, novel, synthetic anti-infective product candidates. These products are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without developing resistance. NovaBay has entered into a licensing and research collaboration agreement with Alcon, Inc. for use of the Aganocide compounds in the eye, ear and sinus, and in contact lens solutions. NovaBay(R) and Aganocide(R) are trademarks of NovaBay Pharmaceuticals, Inc. For more information on NovaBay, visit

Cautionary Information Regarding Forward-Looking Statements

Statements in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, the risk that results obtained in pre-clinical studies may not be obtained in humans, and the risk of unexpected delays in the regulatory process may delay the commencement or completion of clinical trials. Other risks relating to NovaBay's Aganocide compounds, including risks that could cause actual results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Quarterly Report on Form 10-Q/A for the period ended September 30, 2008, under the caption "Risk Factors" in Item 1A of Part II of that report, which was filed with the Securities and Exchange Commission on November 14, 2008.

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
2. NovaBay announces third quarter 2007 financial results
3. NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology: